Clinical trial of argatroban injection combined with edaravone injection in the treatment of atrial fibrillation complicated with cerebral embolism
10.13699/j.cnki.1001-6821.2019.07.001
- VernacularTitle:阿加曲班注射液联合依达拉奉注射液治疗心房颤动合并脑栓塞的临床研究
- Author:
Xia LIN
1
;
Tao-Tao TAO
;
Qiu-Yue CHEN
Author Information
1. 台州医学院附属台州中心医院 神经内科
- Keywords:
argatroban injection;
edaravone injection;
atrial fibrillation;
cerebral embolism;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(7):603-606
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of argatroban injection combined with edaravone injection in the treatment of atrial fibrillation complicated with cerebral embolism. Methods A total of 156 patients with atrial fibrillation complicated with cerebral embolism were randomly divided into control group and treatment group with 78 cases per group. Control group was treated with low molecular weight heparin sodium injection 0. 6 m L per time, bid, hypodermic injection. Treatment group was treated with argatroban injection 60 mg per time, qd, cntinuous intravenous infusion of 24 h, adjusted to 10 mg per time after3-7 d, bid, intravenous infusion + edaravone injection 30 mg per time, bid, intravenous infusion. Two groups were treated for 14 days.The clinical efficacy, coagulation function, serum levels of homocysteine (Hcy) , D-dimer (D-D) , von willebrand factor (vWF) , and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 94. 87 ％ (74 cases/78 cases) and 83. 33 ％ (65 cases/78 cases) with significant difference (P < 0. 05) . After treatment, the main indexes of treatment and control groups were compared: the prothrombin time were (21. 17 ± 2. 78) and (15. 09 ± 2. 05) s, the activated partial thromboplastin time were (44. 06 ± 5. 46) and (31. 15 ± 4. 11) s, the thrombin time were (42. 58 ± 5. 37) and (17. 59 ± 2. 06) s, the international normalized ratio were (1. 85 ± 0. 25) and (1. 31 ± 0. 17) , Hcy were (8. 65 ± 1. 05) and (12. 38 ± 1. 65) μmol·L-1, D-D were (475. 38 ± 50. 48) and (504. 64 ± 62. 34) ng·mL-1, vWF were (18. 56 ± 2. 44) and (22. 35 ± 2. 26) ng · mL-1, the differences were statistically significant (all P < 0. 05) . The adverse drug reactions of treatment group were nausea, vomiting, diarrhea and abnormal liver function, which in control group were nausea, vomiting and diarrhea. The total incidences of adverse drug reactions in treatment group and control group were 7. 69 ％ and 3. 85 ％, the difference was not statistically significant (P> 0. 05) . Conclusion Argatroban injection combined with edaravone injection has a definitive clinical efficacy in the treatment of atrial fibrillation complicated with cerebral embolism, which can effectively reduce the degree of nerve function damage, improve the daily life ability and coagulation function, without increasing the incidence of adverse drug reactions.
